About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

GSK's Relvar Approved by European Authorities

by Kathy Jones on November 19, 2013 at 8:28 PM
Font : A-A+

 GSK's Relvar Approved by European Authorities

British pharmaceutical giant GlaxoSmithKline revealed that European authorities have approved its new inhaled drug Relvar for treating patients with asthma and chronic obstructive pulmonary disease (COPD).

The drug is supposed to be inhaled through a palm-sized device called Ellipta and is made up of a corticosteroid, to reduce inflammation, and a novel long-acting beta-agonist that will help to open the airways.

Advertisement

Relvar has been developed in collaboration with Theravance and has already been approved in the United States, where it has been launched under the brand name Breo, though only for treating COPD patients. The approval by European Commission will see Theravance pay $15 million to GSK while a similar payment will be made once the product is launched across the EU.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Prevent Hacking of Medical Devices: FDA Sounds Alarm
Black Water: Benefits and Uses
World Hypertension Day 2022 - Measure Blood Pressure Accurately, Control It, Live Longer!
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Find a Doctor Diaphragmatic Hernia Loram (2 mg) (Lorazepam) Hearing Loss Calculator Pregnancy Confirmation Calculator Sinopril (2mg) (Lacidipine) Blood Donation - Recipients Post-Nasal Drip Sanatogen Accident and Trauma Care

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use